Morinda citrifolia (Noni) Juice Augments Mammary Gland Differentiation and Reduces Mammary Tumor Growth in Mice Expressing the Unactivated c-erbB2 Transgene by Clafshenkel, William P. et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 487423, 15 pages
doi:10.1155/2012/487423
Research Article
Morindacitrifolia (Noni) JuiceAugments Mammary Gland
Differentiation and Reduces Mammary Tumor Growth in Mice
ExpressingtheUnactivated c-erbB2 Transgene
William P. Clafshenkel,1 Tracy L. King,2 MaryP.Kotlarczyk,1 J. Mark Cline,3
Warren G. Foster,4 V ic k iL.Da vis, 1,5 andPaula A. Witt-Enderby1
1Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA 15282, USA
2Division of Clinical, Social, and Administrative Sciences, Mylan School of Pharmacy, Duquesne University,
Pittsburgh, PA 15282, USA
3Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC 27127, USA
4Department of Obstetrics & Gynecology, McMaster University, Hamiton, ON, Canada L8S 4K1
5Barnes Center, Center for Applied Research & Intellectual Property Development, Clarion University, 840 Wood Street,
Clarion, PA 16214-1232, USA
Correspondence should be addressed to Paula A. Witt-Enderby, wittp@duq.edu
Received 29 December 2011; Accepted 2 February 2012
Academic Editor: Il-Moo Chang
Copyright © 2012 William P. Clafshenkel et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Morinda citrifolia (noni) is reported to have many beneﬁcial properties, including on immune, inﬂammatory, quality of life,
and cancer endpoints, but little is known about its ability to prevent or treat breast cancer. To test its anticancer potential, the
eﬀectsofTahitianNoniJuice(TNJ)onmammarycarcinogenesiswereexaminedinMMTV-neutransgenicmice.Mammarytumor
latency, incidence, multiplicity, and metastatic incidence were unaﬀected by TNJ treatment, which suggests that it would not
increase or decrease breast cancer risk in women taking TNJ for its other beneﬁts. However, noni may be useful to enhance
treatment responses in women with existing HER2/neu breast cancer since TNJ resulted in signiﬁcant reductions in tumor weight
and volume and in longer tumor doubling times in mice. Remarkably, its ability to inhibit the growth of this aggressive form
of cancer occurred with the mouse equivalent of a recommended dose for humans (<3oz/day). A 30-day treatment with TNJ
also induced signiﬁcant changes in mammary secondary ductule branching and lobuloalveolar development, serum progesterone
levels, and estrous cycling. Additional studies investigating TNJ-induced tumor growth suppression and modiﬁed reproductive
responses are needed to characterize its potential as a CAM therapy for women with and without HER2+ breast cancer.
1.Introduction
Approximately 41% of women are utilizing complementary
and alternative medicine (CAM) forms of medicine to
manage their breast cancer [1, 2], including products from
the Morinda citrifolia (noni) plant. An edible and medicinal
tropical plant, Morinda citrifolia, has been used for over
2000 years by Polynesian cultures as an herbal remedy
for infection, arthritis, diabetes, asthma, hypertension, and
pain [3]. All parts of the plant including the roots, bark,
stems, ﬂowers, leaves, and fruit are components in various
combinationsof40knownandrecordedherbalremedies[3],
with the fruit being the most researched [4]. The popularity
of noni has spread from Polynesian and Hawaiian cultures
with its global introduction in the early 1990s [5], and its
products are now readily available in health food stores and
on the Internet.
Several studies reported that noni has multiple cancer
protective properties. Oncostatic activities related to cancer
prevention include reductions in TPA- or EGF-induced
cell transformation [6], reduction in DMBA-induced DNA2 Evidence-Based Complementary and Alternative Medicine
damage and lesion formation [7, 8], and concentration-
dependent free-radical scavenging eﬀects [8–10]. Similarly,
additional anticancer activities, including antiangiogenic
[11] and cancer cell-selective cytotoxic properties [12, 13],
suggest its potential as a treatment to inhibit tumor growth
and progression. Although only a few studies have tested the
cancer inhibitory actions of noni in vivo, one recent study
demonstrated that noni fruit powder had both preventative
and treatment eﬃcacy on rat esophageal cancer induced
by N-nitrosomethylbenzylamine [14]. For breast cancer,
although its oncostatic properties suggest that noni would
inhibit carcinogenesis, there have been no preclinical studies
testing its potential to inﬂuence mammary tumor develop-
ment, except for an abstract reporting that noni inhibits the
initiation stage of DMBA-induced mammary cancer in rats
[7]. Moreover, women are utilizing noni for the prevention
and treatment of breast cancer and as a secondary course of
treatment following conventional chemotherapy [15], even
though its ability to inﬂuence breast cancer development
or progression has not been determined. Therefore, in the
present study, the impact of noni fruit juice administration
on mammary tumor development and tumor growth was
investigated in MMTV-neu transgenic mice. This model
expresses the unactivated rat neu (c-erbB2) gene under
the transcriptional control of the mouse mammary tumor
virus (MMTV) promoter. This mouse model mimics many
features of HER2/neu+ breast cancer, including stochastic
tumor onset, focal tumors arising near hyperplastic tissue,
a long latency period, estrogen-dependent tumor develop-
ment, and metastatic progression to the lungs [16–18]. As no
studies have investigated the inﬂuence of noni on metastatic
progressioninanytypeofcancer,thisstudywithMMTV-neu
mice will examine its ability to inﬂuence the spread of cancer
outside the mammary gland.
Seven case reports of liver damage have been reported
between 2005 and 2011 associated with noni use alone or
in combination with other CAM or traditional medications
[19–22]. Since noni is a common herbal therapy with sales
in U.S.A estimated over $250 million in 2005 [4], these
few reports suggest that hepatotoxicity is a rare event.
In addition, preclinical studies suggest that noni therapies
may have hepatoprotective properties [23, 24]. Concerns
with kidney function have also arisen due to a case report
documenting elevated potassium levels in a patient with
chronic renal insuﬃciency taking noni juice [25]. Therefore,
to determine if long-term administration of a recommended
dose (equivalent to less than 3ounces/day in humans)
shows any liver or kidney toxicity, serum markers and
histopathology were examined in aged mice chronically
treated with noni juice.
In this study, the inﬂuence of a noni fruit juice, Tahi-
tian Noni juice (TNJ), on mammary tumor development,
growth, and metastatic progression in the MMTV-neu mice
wasinvestigated. Additionally, to identify potential responses
that could inﬂuence mammary tumorigenesis, diﬀerentia-
tion in the normal mammary gland, serum hormone levels,
and estrous cycling was examined in sexually mature female
mice treated for 1 month, prior to tumor onset.
2.MaterialsandMethods
2.1. Noni Juice Preparation and Dosage. The Tahitian Noni
Juice or TNJ brand of noni juice (Tahitian Noni Interna-
tional, Utah) was utilized in this study as it supplies the
noni fruit as a puree with no chemical ﬁllers, thickeners,
or preservatives. The puree from ripe noni fruit harvested
in Tahiti used in TNJ contains many nutrients and phyto-
chemicals [26], including iridoids. TNJ is standardized to
contain 30mg to total iridoids/60mL serving. Moreover,
TNJ is one form of noni which has been frequently studied
[3, 8, 23, 27–30] and which is available for use in women.
Administration of TNJ in the drinking water was used to
mimic oral consumption by women. The concentration
used in this study, 10% TNJ v/v added in the drinking
water, would result in the daily consumption of 0.35mL
of TNJ, based on a mouse drinking on average 3.5mL of
water daily. The equivalent human dose would be between
1.5 to 2.75oz (45–80mL) based on daily caloric intake
(1800kcal/day for women versus 14.4kcal/day for mice) to
account for metabolic diﬀerences or average body weight for
each species, respectively. Diﬀerent lots of TNJ were used
across the course of the study. The juice was refrigerated after
opening. TNJ (10%v/v in UV-puriﬁed drinking water) or
vehicle control (UV-puriﬁed drinking water) were provided
ad libitum to animals to mimic women taking TNJ or not.
Water bottles were changed twice weekly.
2.2. Tumor Animal Study. All animal work was approved by
the Duquesne University Institutional Animal Care and Use
Committee (IACUC). The hemizygous female MMTV-neu
mice harboring the neu protooncogene were bred from dizy-
gous transgenic males (FVB/N-Tg(MMTVneu)202Mul/J
[17]) and wild-type FVB/N females (Jackson Laboratory,
Bar Harbor, ME). The female progeny was randomized into
control and 10% TNJ groups at weaning and kept on a
standard 12 hour light/12 hour dark lighting schedule. Both
groups received an isoﬂavone-free diet from conception to
death to eliminate potential confounding eﬀects from these
phytoestrogens. The diet is a modiﬁcation of AIN-93G using
corn oil (Harlan Teklad, Madison, WI, USA) [31]. Treatment
was started after sexual maturity (2 months of age) to
correlate with noni use in adult women and continued until
death. Tumor-free mice were necropsied at the maximum
age of 14 months, unless due to maximum tumor burden,
ulcerated tumors, restricted movement, or illness.
2.3. Tumor Development, Kinetics, and Progression. Mam-
mary tumor onset was determined by weekly palpations of
mammary glands starting at 4 months of age. In growing
tumors, caliper measurements on 2 dimensions were used
to calculate mammary tumor volume using a modiﬁed
ellipsoid formula: mm3 = 1/8[4/3π (large diameter)(small
diameter)2]. During necropsy, resected mammary tumors
were measured in 3 dimensions to calculate tumor volume
using the ellipsoid formula: mm3 = 1/8 [4/3π (diameter
x)(diameter y)(diameter z)]. Mammary tumor doubling
time (DT) was calculated as: DT = (T −T0)·[log2/(logV −
logV0)] [32], where T −T0 represents the length of timeEvidence-Based Complementary and Alternative Medicine 3
(days) between two measurements, V0 is the tumor volume
at the starting point (T0), and V is the tumor volume at the
end time point (T) of the time period.
2.4.TissueHistopathology. Histopathologywascompletedby
a board-certiﬁed veterinary pathologist (J.M.C.) blinded to
the treatment groups on hematoxylin and eosin-stained sec-
tions (Mass Histology Services, Worcester, MA, USA). Renal
andhepatotoxicityandvascularityandnecrosisinmammary
tumor sections were qualitatively assessed. Micrometastases
were quantiﬁed as the total number of emboli or invasive
lesions detected in a lung section as previously described
[31].
2.5. Identiﬁcation and Quantiﬁcation of Blood Vessels in
Tumor Sections. Solid mammary tumors ﬁxed with cold 4%
paraformaldehyde were immunostained for von Willebrand
factor.Tumorsectionswereincubatedwiththeprimaryanti-
body (rabbit anti-von Willebrand factor; 1:100; Millipore,
Ontario, Canada), with secondary antibody (biotinylated
anti-rabbit IgG; 1:500; Vectastain Elite ABC kit, Vector
Laboratories,Ontario,Canada),andwithdiaminobenzidine,
followed by counterstaining with Harris hematoxylin. From
each section, ten regions of interest were randomly identiﬁed
using a grid overlay and immunopositive cells counted by an
investigator blinded to the treatment groups.
2.6.PretumorAnimalStudy. AdditionalhemizygousMMTV-
neu female mice were randomized into the control and 10%
TNJ treatment groups (10/group) and treated as above for
1 month. Estrous cycling was monitored by daily morning
vaginal lavage for the 30 days of treatment. Cells were stained
with Dif-Quick Stain Kit (IMEB Inc., San Marcos, CA) and
cycle stage was determined by established criteria [33]. Mice
were necropsied on the ﬁrst day in estrus after the 30-
day treatment, and cycle stage was reconﬁrmed immediately
prior to euthanasia.
2.7. Steroid Hormone Levels and Mammary Gland Whole
Mounts. Serum 17β-estradiol and progesterone were
assessed using the 17β-estradiol double antibody radio-
immunoassay kit (Siemens, Los Angeles, CA, USA) and
the progesterone Coat-A-Count radioimmunoassay kit
(Siemens, Los Angeles, CA, USA) on animals in estrus with
suﬃcient serum for both assays. Whole mounts were
prepared on inguinal mammary glands ﬁxed in cold 4%
paraformaldehyde by carmine alum staining. Fixed glands
were covered in carmine alum stain (4mM carmanic
acid/0.1mM aluminum potassium sulfate) overnight at
4◦C, rinsed in a graded series of ethanol washes, defatted
and cleared with toluene, and stored in methylsalicylate.
Mammary gland morphology was quantiﬁed from photo-
micrographs using NIH Image J software and based on
guidelines previously reported [34]. The percentage of
ductal tree occupation in the mammary fat pad was
calculated as the ratio of the distance from the center of
the inguinal lymph node to the terminal end bud (TEB)
by the distance from the center of the inguinal lymph
node to the edge of the mammary fat pad. The ratio was
calculated to control for diﬀerence in mammary gland
shape and size between animals. The number of TEBs was
calculated as those terminal structures that were greater than
or equal to 0.015mm2. The number of secondary ducts was
quantiﬁed by locating larger, distinct primary ducts and
counting the number of secondary branches along a 1mm
distance. Ductal thickness was reported as the average of the
transverse distance measured across three separate primary
ducts. The average number of lobuloalveolar structures was
determined by quantifying lobuloalveolar structures in four
separate 16mm2 areas.
2.8. Statistical Analysis. Categorical variables were statisti-
cally analyzed using the Fisher’s exact test. The statistical
diﬀerence between group means was analyzed with the
Student’s t-test when the distribution of the data was
approximately symmetric and with the Mann-Whitney test
when the distribution of the data was skewed. Survival
curves were compared by the Gehan-Breslow-Wilcoxon test.
AnalyseswereperformedusingGraphPadPrism5.0software
with <0.05 P-value considered signiﬁcant.
3. Results
3.1. TNJ Inﬂuence on Mammary Tumor Development and
Growth. Mammary cancer development, growth, and pro-
gression to metastatic disease in the MMTV-neu mouse
modelwereassessedincontroland10%TNJ-treatedanimals
until a maximum age of 14 months. The mean age of mam-
mary tumor latency (259.8 ± 10.6d a y s ,n = 39, for control
versus 266.1±9.9d a y s ,n = 35, for TNJ-treated animals) and
overall mammary tumor incidence (72.2% control, 75.6%
TNJ-treated animals) were unaﬀected by TNJ treatment.
Survival curves for the percent tumor-free animals with age
did not result in a signiﬁcant diﬀerence between the groups
(Figure 1(a)). Mammary tumor multiplicity was also similar
betweengroupswith2.51±0.25versus2.89±0.24mammary
tumors per tumor-bearing mouse for the control (n = 43)
versus the TNJ-treated group (n = 44), respectively. Thus,
no eﬀect of 10% TNJ treatment was observed on mammary
tumor development in the MMTV-neu mouse model.
To investigate the impact of TNJ on tumor growth, the
mammary tumor with the earliest onset in each mouse was
analyzed. Solid mammary tumors were examined for size
and growth analyses as there is intrinsic variability in tumor
volume measurements of cystic tumors, tumor weight and
volume can be aﬀectedbylossoftumorﬂuidduringexcision,
few tumors were cystic in this study, and solid tumors best
represent the eﬃcacy of TNJ against dense, heterogeneous
populations of tumor cells. The average mammary tumor
weight (Figure 1(b))a n dv o l u m e( Figure 1(c))w e r eb o t h
signiﬁcantly lower in the 10% TNJ-treated group. Moreover,
the time between tumor detection and death was not
signiﬁcantlydiﬀerentbetweenthetreatedandcontrolgroups
(Figure 1(d)). These data indicate that the decreased tumor
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Figure 1: Chronic administration of 10% TNJ aﬀects mammary tumor size, but not tumor development, in female MMTV-neu mice. (a)
Survival curves show mammary tumor incidence with age. The percent of tumor-free MMTV-neu females for the control (n = 55) and
TNJ-treated (n = 45) groups up to the maximum age of 14 months are not signiﬁcantly diﬀerent (Gehan-Breslow-Wilcoxon test). Black
arrow indicates maximal primary mammary tumor incidence at approximately 14 months of age. Control: 72.2%; 10% TNJ: 75.6%. (b)
The average weight of the ﬁrst detected mammary tumor for TNJ-treated mice (n = 30) was found to be signiﬁcantly reduced (P<0.010,
Mann Whitney test) compared to control mice (n = 30). Only solid tumors that remained separate from other tumors and had time to grow
to a maximum volume of at least 800mm3 were used for the volume and weight calculations. (c) The average, noncystic mammary tumor
volume for the ﬁrst detected tumor in TNJ-treated mice (n = 30) was smaller than for the control group (n = 30), P<0.038, Mann Whitney
test. Tumor volume was measured on 3 dimensions after dissection. (d) To correlate with length of time each tumor had to grow for the ﬁrst
detected mammary tumor, the time between detection and death was determined for the mice in (b) and (c). The same animals were used
to evaluate both tumor volume and weight (n = 30 for control and n = 30 for TNJ). No signiﬁcant diﬀerence was detected by the Mann
Whitney test. Mean ± SEM are shown; TNJ: Tahitian Noni Juice; ∗indicates signiﬁcance, P<0.05, by the Mann-Whitney test.
the treatment and not to the tumors in the control group
having more time to grow.
Although the ﬁnal tumor weight and volume indicate
growth suppression, these measurements do not indicate
how the size changed with time in the live animal; therefore,
weekly growth patterns and doubling time were compared
between the control and TNJ groups. Weekly growth pro-
ﬁles for control and TNJ-treated mammary tumors show
signiﬁcant size reduction with noni treatment (Figure 2(a)).
Separation of the curves occurs around 9 weeks after tumor
detection when the average volume of the control tumors
is approximately 2500mm3, suggesting that inhibition of
tumor growth by TNJ compared to the control group occurs
as the tumor volume increases. Therefore, tumor doubling
time was determined on speciﬁc ranges of tumor volumes
between 523 and 4000mm3 (approximately 10 × 10mm
to 20 × 20mm); these initial and ﬁnal sizes correlate to
clinically detectable tumor sizes of 1cm and 2cm which
are associated with stage 1 breast cancer. Doubling time
for several volume ranges was analyzed for small (523–
1765mm3,10×10mmto15 ×15mm),intermediate(1765–
3500mm3,1 5× 15mm to 19 × 19mm), and large tumor
sizes (2500–4000mm3,1 7× 17mm to 20 × 20mm) in
mice (Figures 2(b)–2(d). TNJ treatment had signiﬁcant
growth inhibitory eﬀects within the large volume range
of 2500–4000mm3 (Figure 2(d)), which corresponds to the
size of tumors when the growth curves for the control
and TNJ diverge (Figure 2(a)). Tumor doubling times for
the entire size range approached signiﬁcance for reduced
tumor growth with TNJ treatment (523–4000mm3, n = 9Evidence-Based Complementary and Alternative Medicine 5
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Figure 2: Slower tumor growth kinetics in live animals was observed in the 10% TNJ-treated MMTV-neu animals than in the control group
for large tumors. (a) Growth of spontaneously developed mammary tumors was measured weekly with calipers on 2 dimensions. The ﬁrst
solid tumor that was detected ≤5mm in diameter in animals for the control (n = 9) and 10% TNJ (n = 13) groups was compared. These
curves were signiﬁcantly diﬀerent, P<0.0001, as determined by nonlinear regression analysis in Graphpad Prism 5. Due to the inherent
heterogeneity of tumor behavior in this model related to the unique mutations that induce the mammary cancer [35], very rapidly and
slowly growing tumors were excluded. The criteria for exclusion included tumors that grew for less than 2 months (9 weeks) since detection
or did not reach a maximum volume of 900mm3 by 12 weeks after detection. (b) Doubling time for solid mammary tumors with initial
volume ≥532mm3 and that grew to the maximum volume of ≥1765mm3 with at least 2 weeks between these 2 measurements was used to
assess the growth of tumors in the small range. The number of mice examined is shown in the bars for each group. (c) For intermediate size
tumors, the doubling time for tumors growing for 2 weeks or longer within the volume range of 1765–3500mm3 is shown with the number
of mice per groups shown in the bars. (d) 10% TNJ increased mammary tumor doubling time for the large volume range (P = 0.036; 2500–
4000mm3). Only 3 tumors in the control group met the criteria of 2 weeks between the volumes for this range due to the rapid growth of
their larger tumors. For this ﬁgure, only mice with noncystic mammary tumors that remained separate to allow accurate measurement were
included. Mean ± SEM; TNJ: Tahitian Noni Juice; ∗indicates signiﬁcance, P<0.05 as determined by Mann-Whitney test.
and 17, P = 0.067; data not shown). These results suggest
that TNJ treatment results in signiﬁcant growth inhibitory
eﬀects, which likely account for the signiﬁcant reductions in
mammary tumor weight and volume at necropsy noted with
chronic TNJ treatment (Figures 1(b) and 1(c)).
The prevalence of necrosis in mammary tumor sections
(Figure 3(a)) was determined by a board-certiﬁed veterinary
pathologist (J.M.C.), with a nearly signiﬁcant increase in
central necrosis detected with TNJ treatment (P<0.064,
Fisher’s exact test; Table 1). To determine if a potential cause
of the necrosis could be due to poor vascularization of the
tumors, blood vessels were quantiﬁed in tumor sections by
Table 1: Mammary tumors with vascular invasion and central
necrosis detected by histopathology and with blood vessels quan-
tiﬁed by von Willebrand factor immunostaining.
Vascular
invasiona
Necrotic
tumorsa
Immunostained
vessels/20x
ﬁeldb
Control 34.5% (10/29) 27.6% (8/29) 2.4 ±0.2( n = 6)
10% TNJ 13.3% (4/30) 53.3% (16/30) 2.8 ±0.8( n = 6)
aFisher’s exact test, P>0.05.
bMann Whitney test, P>0.05.6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Central necrosis and tumor intravasion are evident in histological MMTV-neu mammary tumor sections. (a) A mammary tumor
from the TNJ-treated group is shown with comedo pattern of central necrosis within each region, magniﬁcation at 100x. Black short arrows
designate necrosis in multiple regions of the tumor. (b) Control group mammary tumor with vascular invasion of tumor cells to form an
embolus within a blood vessel (designated by the black long arrow) is shown, magniﬁcation at 200x.
immunostaining for von Willebrand factor (Figure 4). The
average number of immunopositive blood vessels in the
tumors did not vary signiﬁcantly between groups (Table 1),
although this may be attributed to a small sample size.
Histopathology identiﬁed tumor cells invading into the
blood vessels within the tumor (Figure 3(b)); fewer tumors
in TNJ-treated mice showed evidence of vascular invasion
compared to the control group, which approached signiﬁ-
cance (P<0.072, Fisher’s exact test; Table 1). As vascular
invasion is a crucial step in tumor cells spreading outside
the mammary gland, these data suggest that TNJ may reduce
metastatic progression. However, metastatic incidence for
tumor-bearing mice and the average number of lesions in
mice with micrometastases (with and without extravasion)
were not statistically diﬀerent for the control and 10% TNJ
groups (Table 2). These results suggest that while 10% TNJ
treatment impeded growth of the mammary tumors, it
did not prevent metastatic progression to the lungs in the
MMTV-neu mice, despite less vascular invasion within the
mammary tumors (Table 1).
The possibility of TNJ-induced toxicity was assessed in
aged mice consuming the equivalent of a recommended dose
in women for most of their adult life. Serum levels of the
hepatic enzymes, aspartate transferase (AST) and alanine
transferase (ALT), were examined in the TNJ-treated mice,
sincetheseareconsideredmarkersofliverdamageinhumans
and both were elevated in the case reports on hepatotoxicity
with noni use [19–22, 36, 37]. In addition, serum blood urea
nitrogen (BUN), a marker of renal function, was assessed.
None of these three markers were abnormally elevated or
disproportionate to levels in the control group (Figure 5).
Theseresultsweresupportedbytheabsenceoftoxin-induced
damagetotissueultrastructureinsectionsofliverandkidney
from the 10% TNJ-treated group (data not shown). Thus,
Table 2: Pulmonary metastases within blood vessels and with
extravasion into lung tissue detected by histopathology in tumor-
bearing mice.
Metastatic
incidencea
Average emboli
per mouseb
Average
invasive
lesions per
mouseb
Average
metastases
per mouseb
Control 70.5%
(31/44) 4.4 ±1.04 .4 ±2.58 .8 ±1.6
10% TNJ 74.4%
(32/43) 4.0 ±1.15 .7 ±1.29 .7 ±3.1
aFisher’s exact test, P>0.05 for mice with mammary tumors.
bMann-Whitney test, P>0.05 for mice with metastases.
long-term administration of TNJ in the MMTV-neu model
did not have any detectable adverse eﬀects on the liver and
kidney tissues or markers assessed in this study.
3.2. Reproductive Endpoints in Young TNJ-Treated Mice. The
eﬀects of Morinda citrifolia (noni) juice on estrous cycling
was assessed in MMTV-neu mice treated for thirty days,
starting approximately 5 weeks after the onset of puberty.
While treatment with 10% TNJ did not result in signiﬁcant
changes in the time spent in estrus (9.3 ± 0.6d a y s ,n = 10
for control and 7.9 ± 3.1d a y s ,n = 10 for TNJ), these mice
on average spent approximately one-third of the 30 days
in the proliferative phase and two-thirds in the secretory
phase of the cycle (Figure 6(a)). In contrast, the control
group spent approximately the same number of days in
each phase. Alteration in the cycling pattern over the thirty-
day period suggests that TNJ treatment may impact the
hormonal pathways which regulate the estrous cycle.Evidence-Based Complementary and Alternative Medicine 7
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Figure 4: Example sections for the negative control (no primary antibody) and for immunostaining with anti-von Willebrand factor in
MMTV-neu mammary tumors. (a) Staining was absent in a negative control section. The primary antibody was replaced with nonimmune
serum (1:100) for negative control slides. (b) Immunohistochemistry resulted in isolated clusters of epithelial cells (arrow) in sections of
mouse mammary tumors stained with anti-von Willebrand factor antibody (1:100). Sections were counterstained with Harris hematoxylin.
Original magniﬁcation 200x.
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Figure 5: Chronic administration of 10% TNJ does not elevate serum levels of markers for hepatic renal toxicity in 14-month-old female
MMTV-neu mice. (a) Serum alanine aminotransferase (ALT), a hepatic serum marker, in control, n = 7, and 10% TNJ-treated, n = 7, mice.
(b) Serum aspartate aminotransferase (AST), a marker of liver damage, in control, n = 6, and 10% TNJ, n = 6, groups. (c) Serum blood
nitrogen urea (BUN), a renal function marker, in control, n = 6, and 10% TNJ, n = 2, groups. Only animals necropsied within 48 hours of
the assay were used to analyze BUN levels. No signiﬁcance was detected for any of the markers, P>0.05; P values determined by Student’s
t-test. Mean ± SEM are shown; TNJ: Tahitian Noni Juice.
Serum levels of the ovarian hormones, 17β-estradiol and
progesterone, were analyzed in the 3-month-old mice in
estrus. Serum levels of 17β-estradiol were not signiﬁcantly
aﬀected by the 30-day treatment, but there was a trend
t o w a r d se l e v a t e dl e v e l sw i t h1 0 %T N J( Figure 6(b)). Circu-
lating levels of progesterone from the same animals were sig-
niﬁcantly reduced in the 10% TNJ-treated group compared
to control levels (Figure 6(c)). As the decreased progesterone
levels occurred during the phase of the cycle when its levels
are low (estrus), these results suggest that the baseline levels
of progesterone are modiﬁed by TNJ administration.
Due to changes in the estrous cycling and serum
progesterone levels, uterine stimulation was investigated in
the mice treated short term (30 days) or long term (up to 12
months) with TNJ. The lower progesterone levels for mice
in estrus (Figure 6(c)) could result in higher uterine wet
weights in this phase of the cycle due to less of this uterine
protective hormone available to counteract the estrogen-
induced stimulation, especially with the trend to higher 17β-
estradiollevels(Figure 6(b)).However,nochangesinuterine
weight were observed in the aged (Figure 6(d))o ry o u n g
mice (Figure 6(e)) in estrus. In addition, at times of low
estrogen (secretory phase), no increases in uterine weight
were detected after long-term TNJ treatment (Figure 6(d)).
Therefore, the signiﬁcant changes in progesterone levels and
cycling did not result in an observable eﬀect on this highly
hormone-responsive tissue. Body weights in the young and
agedmicewerealsonotsigniﬁcantlydiﬀerentinthe1-month
and long-term TNJ-treated mice compared to the control
group (Figure 6(f)).
Ovarian hormones control morphological changes in
breast architecture in both humans and rodents [38–40]. In
mice, estrogen regulates the elongation of the primary mam-
mary ducts into the mammary fat pad, while progesterone8 Evidence-Based Complementary and Alternative Medicine
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Figure 6: TNJ treatment results in more days in the secretory phase of the estrous cycle over a 30-day period and in reduced serum
progesterone levels. (a) Eﬀects on estrous cycling were analyzed in virgin, tumor-free MMTV-neu mice over thirty days of treatment with
10% TNJ. The time spent in the proliferative (follicular) phase decreased and increased in the secretory (luteal) phase in females treated
with 10% TNJ compared to the control animal over the 30-day period (between ages 2 and 3 months), P = 0.002 by the Mann-Whitney
test (n = 10 for each group). Vaginal smears in the morning were used to determine secretory phase stages (diestrus and metestrus) and
proliferativephasestages(proestrusandestrus).(b)Serum17β-estradiol(E2)lev elsforcontrol(n = 5)and10%TNJ-treatedfemales(n = 6)
were measured by radioimmunoassay in virgin, tumor-free 3-month-old MMTV-neumice that were in estrus at necropsy. Serum levels were
not signiﬁcantly diﬀerent between groups. (c) Serum progesterone (P4)l e v e l sf o rc o n t r o l( n = 7) and 10% TNJ-treated females (n = 8)
were measured in the same mice analyzed for 17β-estradiol levels (in estrus). Serum progesterone levels, as analyzed by Student’s t-test, were
signiﬁcantly reduced in mice receiving 10% TNJ for 1 month (P = 0.029). (d) For tumor study mice in estrus or in the secretory phase
(metestrus and diestrus) at the time of necropsy, uterine wet weight normalized to body weight (Ut wt/BW) was not signiﬁcantly diﬀerent
for the control and 10% TNJ-treated groups. Control estrus (n = 12) and secretory phase (n = 31); TNJ estrus (n = 15) and secretory phase
(n = 20). Mice used for uterine weights in the tumor study were, on average, around 1 year of age and were euthanized for maximum age or
tumor size. (e) For the 3-month-old females in the pretumor study, uterine wet weight normalized to body weight (Ut wt/BW) for mice in
estrus just prior to necropsy were not signiﬁcantly diﬀerent for either treatment group; control (n = 6), TNJ (n = 9). (f) Body weights after
euthanasia for young animals treated for 1 month (3-month-old mice, n = 10) or aged mice (n = 58, control; n = 55, TNJ) in the tumor
study in TNJ-treated and control groups were signiﬁcant by 2-way ANOVA for age (P<0.001), but not treatment. Mean ± SEM are shown;
TNJ: Tahitian Noni Juice; ∗indicates signiﬁcance, P<0.05 by Mann Whitney or Student’s t-test.
stimulates secondary and tertiary branching and lobuloalve-
olar development [40]. Qualitative assessment from whole
mounts of the inguinal mammary glands of TNJ-treated
mice showed a much higher degree of ductal branching
and exhibited marked lobuloalveolar development (Figures
7(e)–7(h)) compared to the glands from the control mice
(Figures 7(a)–7(d)). To quantify these speciﬁc parameters
associated with progesterone actions, signiﬁcantly more sec-
ondary ducts along a 1mm length of the primary duct were
detected in the TNJ-treated group compared to the control
group(Figure 7(i)). Additionally, the average number of lob-
uloalveolar structures was signiﬁcantly higher in the 10%
TNJ-treated group (Figure 7(j)). Other analyzed parameters
associated with estrogenic activity in the mammary gland,Evidence-Based Complementary and Alternative Medicine 9
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Figure 7: Thirty-day treatment of virgin, tumor-free MMTV-neu mice with 10% TNJ results in morphological diﬀerences in mammary
gland diﬀerentiation. Representative photomicrographs shown for 2 animals in the control (panels a–d) and 10% TNJ-treated (panels e–h)
groups; animal 1 is shown in panels (a) and (b) for control and (e) and (f) for TNJ groups and animal 2 is shown in panels (c) and (d) for
controland(g)and(h)forTNJgroups.Forpanels(a)and(e)imageswerecapturedattheterminusoftheglandatmagniﬁcation13x;panels
(b) and (f) show enlargement of the area outlined by the dashed box at magniﬁcation 26x. For panels (c) and (g), images depict the area
aroundtheinguinallymphnodetoqualitativelyassessthedegreeofductalbranchingandlobulardiﬀerentiationatmagniﬁcation13x;panels
(d) and (h) are the magniﬁed portion of the gland in the adjacent micrograph outlined by the dashed boxes, magniﬁcation 26x. Black arrows
identify lobular structures. Inset bars measure 1mm. The graphs in panels (i) and (j) show quantiﬁcation of the diﬀerentiation evident
in the photomicrographs for the mice treated for 30 days with 10% TNJ. (i) The number of secondary ducts was quantiﬁed by locating
larger, distinct primary ducts and counting the number of secondary branches along a 1-mm distance. Secondary ductule branching in the
mammary glands of virgin, tumor-free MMTV-neu mice is signiﬁcantly increased, P = 0.0001; control, n = 4, and TNJ, n = 5. (j) The
average number of lobules was determined by quantifying lobuloalveolar structures in four separate 16mm2 areas for each animal. The
number of lobules was also signiﬁcantly increased by TNJ in the same animals analyzed for secondary branching, P = 0.0015. Mean ± SEM
are shown; TNJ: Tahitian Noni Juice; ∗∗indicates signiﬁcance, P<0.002; ∗∗∗indicates signiﬁcance, P = 0.0001 by Student’s t-test.10 Evidence-Based Complementary and Alternative Medicine
including the number of terminal end buds at the leading
edge of the ductal tree, the average size of terminal end
bud structures, and the average thickness of primary ducts,
were not signiﬁcantly diﬀerent between the control and
TNJ-treated animals (data not shown). Collectively, the
observed responses induced by TNJ treatment (increased
ductal arborization and lobule formation) correlate with
known progesterone actions even with lower progesterone
levels in MMTV-neu mice in estrus.
4. Discussion
4.1. Mammary Tumor Outcomes with TNJ Treatment. TNJ
treatment primarily aﬀected mammary tumor growth with
no observable eﬀects on tumor latency and incidence in the
MMTV-neu model of HER2/neu breast cancer. These data
suggest that, at the dose tested, noni juice may not protect
women against the development of HER2+ breast cancer.
However, it is unknown if higher doses may be able to inhibit
MMTV-neu mammary and HER2+ breast carcinogenesis or
if TNJ may have chemopreventative activity against other
forms of breast cancer, such as ER+ breast tumors. Some
previous preclinical cancer studies have injected the noni
treatments [4]; however, that delivery method would not
compare to oral ingestion by women or account for its
potential metabolism by the liver. In the MMTV-neu mice,
TNJ was supplied orally to correlate to consumption by
women. Therefore, if TNJ acts similarly in women and
MMTV-neu mice, for women taking the recommended
dose of TNJ for other disorders or diseases for which
noni has been used (such as wound healing, diabetes, high
bloodpressure,immunestimulation,arthritis,inﬂammatory
disorders, pain, etc.), its lack of eﬀect on mouse mammary
tumor development may suggest that this CAM therapy
would not increase a woman’s risk of developing HER2+
breast cancer.
Tumor growth was signiﬁcantly inhibited in the MMTV-
neu mice treated with TNJ; the growth reduction of solid
tumors was evident in smaller ﬁnal tumor weights and
volumes (Figure 1) and in longer doubling time for large
mouse tumors (Figure 2). These ﬁndings are in agreement
withanotherstudywhichreportedsuppressedEhrlichascites
tumor growth in Balb-c mice treated with noni juice [41].
The most signiﬁcant growth inhibition in solid mammary
tumors from TNJ-treated mice occurred in the size range
of 2500–4000mm3 (approximately 1.7cm to 2.0cm diam-
eter, Figure 2(d)) and was evident in the weekly tumor
growth curves (Figure 2(a)). The growth inhibitory eﬀect
of TNJ administration is an important ﬁnding given the
aggressiveness, hormone-independence, and heterogeneity
of tumors in this model. HER2/neu overexpression has been
implicated in 20–30% of breast cancers and is inversely
correlated with patient survival [42, 43]. These tumors
are diﬃcult to treat and are most responsive to targeted
therapies for the HER2 antigen, such as trastuzumab [44].
The ability of TNJ to inhibit the growth of the mouse
tumors, without requiring doses above those recommended
for healthy women, suggests that further testing for its
potential as a complementary therapy for HER2+ breast
cancer may be warranted.
4.2. Possible Modes of TNJ Mammary Tumor Growth Inhibi-
tion. Onepossibleactionforthetumorgrowthinhibitionby
TNJ may be as an angiogenesis inhibitor. Noni is reported to
be a potent inhibitor of angiogenesis by reducing new vessel
generation from placental vein explants and inducing degen-
eration and apoptosis within established capillary networks
in human breast tumor explants [11]. The ability of TNJ to
inhibit, but to not completely arrest or cause regression of
neu-inducedtumorgrowth,isconsistentwiththecapabilities
of other angiogenesis inhibitors, both in this model and
in breast cancer patients [45, 46]. The increase in central
necrosis in mammary tumors may allude to antiangiogenic
and/or cytotoxic actions of TNJ treatment; however, the
lack of a diﬀerence in von Willebrand factor immunos-
taining between control and TNJ-treated tumors does not
support this potential mechanism (Table 1). Nonetheless,
due to the inherent variability in mammary tumors in this
mouse model [47], evidence that other treatments with
antiangiogenicactionsinhibittumorgrowthinneumice[45,
48] and, unlike noni, that antiangiogenic pharmaceuticals
are associated with a myriad of side eﬀects [46], further
investigation on the possible angiogenic inhibitory actions of
noni for suppressing breast tumor growth may be justiﬁed.
Tumor growth inhibition by TNJ may also be mediated
by immune modulation. Noni is reported to stimulate the
immune system [49] and to modify the release of cytokines
from immune cells [50, 51]. A case report on two cancer
patients taking noni suggested that immune responses may
havearoleintheirlong-termsurvival[52].Itsantitumorand
immunomodulatoryactivitieshavebeenlinkedinpreclinical
studies using an isolated polysaccharide-rich substance from
noni (noni-ppt) in Lewis lung carcinoma model [50, 53]a n d
withafermentednoniexudate(fNE)inmousesarcomaS180
and Lewis lung carcinoma xenografts [54]. The increased
survival of the tumor-bearing mice treated with noni-ppt
wasblockedwithspeciﬁcinhibitorsformacrophages,T-cells,
and natural killer cells [50, 53]. For fNE, the pronounced
increased survival of fNE-treated C57BL/6J mice injected
with S180 cells was reduced in B6 nude mice with a T
cell deﬁciency and was completely blocked in beige mice
with a severe natural killer cell deﬁciency [54]. These
studies suggest that these immune cells are essential for
inhibiting tumor growth by both noni-derived treatments
and, therefore, may also be involved in suppression of
MMTV-neu mammary tumors. Plus, the MMTV-neu mouse
model has been documented to be a good model for the
immune tolerance observed in HER2/neu breast cancer
patients[55].Toleranceallowstumorstogrowrapidlyandbe
resistanttodeathbecausetheircellsarenotrecognizedbythe
immunesystem.Mechanismstoactivatetheimmunesystem,
such as by inhibiting regulatory T cells, enhanced growth
inhibition of implanted neu-overexpressing tumors by neu-
targeted vaccines [56, 57]. Tumor growth in the MMTV-neu
model with activated neu transgene is also suppressed by
treatment with cytokines, such as IL-4 and IL-12 [58, 59],Evidence-Based Complementary and Alternative Medicine 11
which have both been reported to be modiﬁed by noni
treatments [50, 51]. Therefore, as immunomodulation is
eﬀective at reducing tumor growth in neu mammary tumor
mouse models, this activity of TNJ may be at least partially
responsible for inducing similar inhibition in this study.
Other noni activities have been proposed to inﬂuence
tumor behavior, such as antioxidant and anti-inﬂammatory
actions, which have deﬁned roles in breast cancer [60, 61].
For example, esophageal tumor inhibition by noni resulted
in higher serum antioxidant capacity [14]. In a clinical
trial, TNJ also reduced superoxide anion radicals and lipid
hydroperoxide in smokers [27]. The anti-inﬂammatory
actions of noni, including its ability to directly inhibit COX-
2 activity and its corresponding PGE2 levels [4, 62], may
also be important for the tumor inhibition since COX-2 is
critical for neu-induced tumorigenesis [63, 64]. Therefore,
multiple activities may play a role in the TNJ-induced tumor
inhibition in the MMTV-neu mice.
Although signiﬁcant growth inhibitory actions were
demonstrated in TNJ-treated mice and histopathology sug-
gests that it inhibits tumor cell invasion into the vascular
network in mammary tumors, a corresponding reduction
in the incidence of lung micrometastases was not observed.
However, these data do not disqualify TNJ as a possible
therapy for inhibiting metastatic progression since the
HER2/neu tumors are aggressive and may require a higher
dose than recommended for healthy individuals or tested in
this study. In addition, even though it was ineﬀective alone,
TNJ could have a beneﬁcial eﬀect of decreasing metastatic
incidence when used in combination with other forms of
chemotherapy. Moreover, the lack of eﬀect on metastatic
incidence in the MMTV-neu mice suggests that TNJ would
not increase risk if the primary tumor cells are spreading
outside the breast, which would be important for breast
cancer patients taking TNJ for other health beneﬁts or
continuing problems that preceded cancer. Noni is reported
in preclinical and clinical studies to increase energy and
quality of life and decrease pain [4, 65, 66]; thus, its use
may have potential beneﬁts for cancer patients besides or in
addition to its antitumor properties.
4.3. Lack of Hepato- and Renal Toxicity by TNJ. TNJ did not
elevate serum markers of renal and hepatotoxicity (Figure 5)
or change histopathology of either organ in mice treated
for 1 year with the mouse equivalent of the recommended
dose for humans (<3oz daily). Previous studies showing
lack of toxicity were performed with high doses of noni for
shorter time periods, such as 90mL/kg daily for 3 months
in rats [29] and 750mL/day for 28 days in humans [30, 67];
but, the ﬁndings in the MMTV-neu mice demonstrate no
liver or kidney toxicity with long-term oral administration
of a recommended dose. Still, a few clinical case reports
have documented that consumption of noni juice can
induce reversible hepatotoxicity (except in one case) or
hyperkalemia in one patient with chronic renal insuﬃciency
[19–22, 25, 36, 37]. The fact that both liver transaminases
were normal in mice in contrast to their elevated levels in
the case reports suggests that long-term TNJ consumption
did not adversely aﬀect the liver. While the dose of TNJ
used in the experimental design is based on the normal
recommended dose for consumers, it is important to state
thatourinbredmousemodelexhibitslessvariabilitythanthe
human population. Therefore, it is possible that a subset of
humans may be susceptible to side eﬀects or adverse events
associated with short- or long-term TNJ use. Yet, based on
its prevalent use in humans with relatively few reports of
toxicity [5], the absence of adverse eﬀects in other clinical
and preclinical studies [4, 26, 29, 30, 67], and the lack of
toxicity with long-term TNJ administration in MMTV-neu
mice, noni consumption appears to be safe for the majority
of the adult human population.
4.4.TNJEﬀectsonMammaryGlandDiﬀerentiation,Hormone
Levels, and Reproductive Tract. Enhanced mammary gland
diﬀerentiation has been inversely correlated with malignant
potential of breast epithelial cells. That is, it is proposed
that if epithelial cells in undiﬀerentiated lobules never
diﬀerentiate(e.g.,nulliparouswomen),thentheywillremain
targets of neoplastic transformation [68–70]. Conversely, if
diﬀerentiation is induced by pregnancy, these epithelial cells
become refractory to transformation and have a protec-
tive genomic signature against breast cancer development
[68–70]. However, in the MMTV-neu mice, the increased
secondary branching and lobuloalveolar development with
TNJ did not result in any protective or adverse eﬀects on
mammary tumor development as latency, incidence, and
multiplicity were unaﬀected. But, perhaps the enhanced dif-
ferentiation in TNJ-treated mouse mammary glands aﬀects
the tumors that subsequently develop in these glands to
result in slower tumor growth.
The increase in secondary branching and number of
lobules with TNJ treatment (Figures 7(i) and 7(j)) are
associated with progesterone actions in the mammary gland
[40] but are paradoxical to the reduced progesterone levels
detected during estrus (Figure 6(e)). Since the hormone
levels were not measured during the secretory phase, it is
unknown if a corresponding reduction in progesterone also
occurs during metestrus and diestrus. If so, possibly the
amplitude change between the peak (secretory phase) and
nadir (proliferative phase) may be more important than
speciﬁc progesterone levels and could stimulate enhanced
mammary branching and lobule formation. Alternatively, it
is possible that the longer time the TNJ-treated mice spent
in the secretory phase (Figure 6(a)) may account for the
enhanced diﬀerentiation that is stimulated in this phase of
the estrous cycle.
Noni is reported to have weak estrogenic activity in
vivo [71], and the ﬂavone glycosides in noni fruit have
been classiﬁed as phytoestrogens [72]. Thus, the estrogenic
components of TNJ and/or the trend to higher 17β-estradiol
levels in the mice (Figure 6(b)) could potentially upregulate
progesterone receptor levels in the uterus and mammary
glands of TNJ-treated mice to enhance progesterone sensi-
tivity. However, a uterotropic study in immature rats did
not ﬁnd evidence of estrogenic uterine stimulation by noni
extract [73]. The unmodiﬁed uterine wet weights in the
MMTV-neu mice with short- or long-term TNJ treatment
coincide with their ﬁndings (Figures 6(d) and 6(e)). The12 Evidence-Based Complementary and Alternative Medicine
studyinimmatureratsreportedevidenceofantiestrogenicity
for noni extract coadministered with 17α-ethynylestradiol
[73], but this activity was not observed in intact MMTV-neu
miceasuterineweightswerenotreducedwithTNJtreatment
in the presence of endogenous estrogens. Therefore, at the
dose tested, estrogenic and/or antiestrogenic properties of
TNJ are unlikely to be involved in the uterine and mammary
tissue responses in the mice.
Estrous cycling over a 30-day period was signiﬁcantly
modiﬁed by TNJ treatment resulting in more days in the
secretory phase with a corresponding reduction in the
proliferative phase (Figure 6(a)). It is unknown whether this
eﬀect is related to the lower progesterone levels. Nonetheless,
included in the beneﬁcial claims for noni use is its ability
to inﬂuence menstrual cycle regulation and cramps, though
these beneﬁts lack scientiﬁc veriﬁcation [74]. The altered
estrous cycling in MMTV-neu mice by TNJ provides the
initial scientiﬁc support for these claims and suggests that
noni may have beneﬁts on women’s reproductive health.
4.5. TNJ versus Other Noni Products. The results of this
study indicate the potential beneﬁts of TNJ on cancer and
reproductive outcomes. As there are many diﬀerent products
derived from noni fruit and other parts of the plant, it is
unknown if other products would elicit the same eﬀects.
One class of active phytochemicals in noni is the iridoids,
which has many beneﬁcial activities, including anticancer,
antioxidant, anti-inﬂammatory, and immunomodulating
properties [75].Astheiridoidcontentinnonifruitharvested
in diﬀerent tropical regions and in parts of the noni plant
(such as seed, root, ﬂower, and leaf) vary considerably
[76], other noni products could result in diﬀering levels of
response on the outcomes investigated in the MMTV-neu
m i c e .H o w e v e r ,a sm a n yc o m p o n e n t so fn o n ij u i c eh a v eb e e n
identiﬁed whichmay havebeneﬁcialeﬀects[4,26],theuseof
noni fruit puree allows the inﬂuence of additive and possible
synergistic actions of these components versus reductionism
to isolated components which are unlikely to have the full
beneﬁts of the fruit.
TNJ also contains a small percentage of grape and
blueberry juice to enhance palatability, but these juices also
containchemicals,whichhaveanticancerproperties[77,78],
have been reported to inﬂuence cancer development and/or
tumor growth [14, 79–82] ,a n dc o u l da d do rs y n e r g i z ew i t h
the noni juice. Thus, it is possible that, even in their low
amounts in TNJ, these other juices could contribute to the
tumor growth inhibition in the MMTV-neu mice. However,
in a clinical trial using grape/blueberry juices as a placebo,
only TNJ with the noni puree resulted in the beneﬁcial
reduction of lipid peroxidation and reactive oxygen species
in heavy smokers [27]. Their ﬁndings suggest that the small
percentage of other juices would not be responsible for the
reduced tumor growth in the mice; however, as diﬀerent
outcomes were investigated, these juices may still have a
partial role in inhibiting mammary tumor growth.
4.6. Summary. TNJ signiﬁcantly suppressed tumor growth
in a model that mimics HER2-overexpressing breast cancer.
The fact that these eﬀects occurred using a dose in mice
that equates to the recommended human dose is remark-
able considering the aggressive and unresponsive nature
of HER2/neu-positive, hormone-independent breast cancer.
AlthoughfurtherstudieswillberequiredtodetermineifTNJ
has analogous actions in women as those discovered in this
mouse model, tumorigenesis in MMTV-neu mice has many
similaritiestohumanHER2+ breastcancer[16–18].Withthe
possibility of similar actions in both species, for TNJ use in
women with undetected breast cancer, these ﬁndings suggest
that its growth inhibitory eﬀects may prolong the time until
thecancerisdiagnosed,asthetumorsizeatwhichsigniﬁcant
growth suppression was observed (1.5–2cm in diameter) is
within the range of early tumor detection in women (stage
1 breast cancer). For women with HER2+ breast cancer,
TNJ may suppress tumor growth to allow additional time
for surgical or other therapeutic interventions and may
enhance the chemotherapy response, as has been reported
for noni in rodent models for other types of cancer [41, 53].
Thus, timing, either before or after cancer detection, may
ultimately result in improved patient prognosis. Although
tested in a hormone-independent model, some of the signif-
icant ﬁndings reported here for TNJ administration may be
applicable to women with hormone-responsive breast cancer
and warrant further investigation in appropriate preclinical
models. Thus, given the growth inhibitory eﬀects of TNJ
on HER2/neu tumors and the lack of adverse eﬀects in
the MMTV-neu model, TNJ may be able to enhance the
manageability of HER2+ breast cancer to prolong patient
survival when administered as a complementary therapy. As
more women are seeking natural therapies for general well-
being and for treating cancer to reduce the undesired side
eﬀects associated with many pharmaceutical options, further
clinical and preclinical studies are needed to evaluate the
potential of noni for breast cancer treatment and quality of
life issues.
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